More than 200 advocates gathered on Capitol Hill during the Cystic Fibrosis Foundation's 14th Annual March on the Hill, championing antibiotic research and development and other policy needs on behalf of people with CF.
Site Search
Showing 81 - 84 of 84 results
News
|
|
3 min read
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
News
|
|
4 min read
News
|
|
2 min read
News
|
|
1 min read